Schedule 13D ownership disclosure

Palvella Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 697947109

Event date: 2024-12-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Kaupinen WesReported CIK 0001918142

    Shares: 1,644,869.00 · Class: 14.6%

  • Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019

    Shares: 781,409.00 · Class: 6.9%

  • Christine L. Kaupinen

    Shares: 1,562,818.00 · Class: 13.9%

  • Christine L. Kaupinen 2019 Irrevocable Trust dated February 28, 2019

    Shares: 781,409.00 · Class: 6.9%

  • Michael Christopher

    Shares: 781,409.00 · Class: 6.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001437749-24-038167
Form type
SCHEDULE 13D
Filer
Kaupinen Wes
CIK
CIK 1918142
Filed
Dec 20, 2024
Reporting period
Dec 13, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub